Free Trial

Ascendis Pharma A/S (ASND) Competitors

Ascendis Pharma A/S logo
$207.12 -1.59 (-0.76%)
Closing price 04:00 PM Eastern
Extended Trading
$206.46 -0.66 (-0.32%)
As of 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ASND vs. ARGX, TAK, ONC, INSM, BNTX, TEVA, GMAB, SMMT, VTRS, and RDY

Should you be buying Ascendis Pharma A/S stock or one of its competitors? The main competitors of Ascendis Pharma A/S include argenex (ARGX), Takeda Pharmaceutical (TAK), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Viatris (VTRS), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

Ascendis Pharma A/S vs. Its Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

60.3% of argenex shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, argenex had 24 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 36 mentions for argenex and 12 mentions for Ascendis Pharma A/S. argenex's average media sentiment score of 0.77 beat Ascendis Pharma A/S's score of 0.61 indicating that argenex is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascendis Pharma A/S
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
argenex
16 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

argenex has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$393.54M32.47-$409.12M-$5.16-40.14
argenex$2.25B22.16$833.04M$19.5041.83

argenex has a net margin of 40.98% compared to Ascendis Pharma A/S's net margin of -54.94%. argenex's return on equity of 21.06% beat Ascendis Pharma A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Ascendis Pharma A/S-54.94% N/A -24.31%
argenex 40.98%21.06%18.25%

Ascendis Pharma A/S has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, argenex has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Ascendis Pharma A/S presently has a consensus price target of $248.29, indicating a potential upside of 19.88%. argenex has a consensus price target of $817.53, indicating a potential upside of 0.23%. Given Ascendis Pharma A/S's higher possible upside, equities analysts clearly believe Ascendis Pharma A/S is more favorable than argenex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascendis Pharma A/S
1 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.88
argenex
0 Sell rating(s)
2 Hold rating(s)
20 Buy rating(s)
2 Strong Buy rating(s)
3.00

Summary

argenex beats Ascendis Pharma A/S on 14 of the 17 factors compared between the two stocks.

Get Ascendis Pharma A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ASND vs. The Competition

MetricAscendis Pharma A/SMED IndustryMedical SectorNASDAQ Exchange
Market Cap$12.88B$3.38B$6.11B$10.46B
Dividend YieldN/A2.29%5.73%4.77%
P/E Ratio-40.1422.7785.3627.36
Price / Sales32.47482.84606.87135.08
Price / CashN/A46.7037.4661.86
Price / Book-110.1710.5512.426.81
Net Income-$409.12M-$52.58M$3.32B$276.80M
7 Day Performance-1.43%1.09%1.01%0.27%
1 Month Performance6.42%16.09%10.75%8.31%
1 Year Performance62.70%18.41%76.20%35.60%

Ascendis Pharma A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ASND
Ascendis Pharma A/S
3.1864 of 5 stars
$207.12
-0.8%
$248.29
+19.9%
+62.5%$12.88B$393.54M-40.141,017News Coverage
Analyst Forecast
Analyst Revision
ARGX
argenex
3.7213 of 5 stars
$787.94
-1.5%
$802.90
+1.9%
+49.6%$48.96B$3.05B40.411,599Trending News
Analyst Forecast
Analyst Revision
TAK
Takeda Pharmaceutical
2.5802 of 5 stars
$14.56
-0.3%
N/A-3.8%$46.46B$30.09B48.5347,455News Coverage
Analyst Forecast
ONC
BeOne Medicines
1.8611 of 5 stars
$344.53
+0.2%
$336.30
-2.4%
N/A$37.69B$3.81B-199.1511,000
INSM
Insmed
2.9598 of 5 stars
$158.28
+0.7%
$149.06
-5.8%
+114.9%$33.22B$363.71M-27.721,271Analyst Forecast
BNTX
BioNTech
2.1698 of 5 stars
$105.16
-0.3%
$134.56
+28.0%
-14.6%$25.36B$2.98B-65.726,772Analyst Forecast
TEVA
Teva Pharmaceutical Industries
3.2903 of 5 stars
$19.99
-0.1%
$25.57
+27.9%
+16.7%$22.95B$16.54B-124.9436,830
GMAB
Genmab A/S
4.1944 of 5 stars
$33.31
-0.7%
$40.80
+22.5%
+38.4%$21.55B$3.12B16.742,682Trending News
Analyst Forecast
Analyst Revision
High Trading Volume
SMMT
Summit Therapeutics
2.9901 of 5 stars
$22.15
+3.4%
$31.29
+41.2%
+7.4%$15.92B$700K-21.93110Analyst Upgrade
Gap Up
VTRS
Viatris
2.3173 of 5 stars
$10.13
-0.6%
$10.40
+2.7%
-12.8%$11.88B$14.74B-3.4932,000News Coverage
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7077 of 5 stars
$14.12
-0.3%
$16.95
+20.0%
-11.6%$11.82B$3.81B21.3927,811News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:ASND) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners